

Oregon Board of Pharmacy

BOARD MEETING AGENDA

Meeting Location:

Portland State Office Building
800 NE Oregon Street, Portland, OR 97232

April 3-4, 2019

The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs.

Wednesday, April 3, 2019 @ 8:30AM – Conference Room 1A

Thursday, April 4, 2019 @ 8:30AM – Conference Room 1A

≈ If special accommodations are needed for you to attend or participate in this Board Meeting, please contact Loretta Glenn at: (971) 673-0001. ≈

WEDNESDAY, APRIL 3, 2019

I. 8:30AM OPEN SESSION, Rachael DeBarmore, R.Ph, Presiding

- A. Roll Call
- B. Agenda Review and Approval *Action Necessary*

II. Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public

III. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k).

- A. Items for Consideration and Discussion:
 - 1. Deliberation on Disciplinary Cases and Investigations
 - 2. Personal Appearances
 - 3. Deficiency Notifications
 - 4. Case Review

IV. OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin some of the following scheduled agenda items - time permitting at approximately 3:30PM.

THURSDAY, APRIL 4, 2019

8:30AM

V. OPEN SESSION, Rachael DeBarmore, R.Ph, Presiding

- A. Roll Call
- B. Motions for Contested Cases & Disciplinary Action – *Efremoff* *Action Necessary*

VI. GENERAL ADMINISTRATION

- A. Rules
 - *First Look ** Second Look *** Third Look
 - 1. Review Rulemaking Hearing Report & Comments – none

Agenda – April 3-4, 2019

NOTE: The Board may rearrange its agenda to accommodate the Board or members of the public.

Page 1 of 4

2. Consider Adoption of Rules – none
3. Consider Adoption of Temporary Rules – none
4. Rules Update - none
5. Consider rules and send to Rulemaking Hearing
 - Div 110 – Fees - **#A** MacLean *Action Necessary*
6. Policy Issues for Discussion / Updates:
 - Div 045 Compounding – RAC update - MacLean

B. Public Health and Pharmacy Formulary Advisory Committee
Karbowicz/MacLean/Efremoff

1. Committee Meeting and Recommendation update
2. Consider rules & send to Rulemaking Hearing – none

C. Discussion Items:

1. Waiver Requests: none
2. TCVP: none
3. Other:
 - a. R.Ph. Renewal and CE requirements update **#B1** - Hennigan
 - b. Cannabidiol sales – **#B** Efremoff/Gin *Action Necessary*
 - c. Strategic Planning update – Schnabel/MacLean
 - d. Annual elections in June – process reminder – DeBarmore/MacLean

D. Annual Business Meeting - MacLean

(In the interest of time, the Board will consider a few items at this meeting to allow more time for other discussion at the June meeting)

- 1) Approval of ACPE Accredited Schools & Colleges of Pharmacy and
Approval of ACPE Continuing Education Process **#** *Action Necessary*
- 2) Approve current list of Fed. List of Controlled Substances **#C2** *Action Necessary*
- 3) Schedule of Administrative Fees **#** *Action Necessary*
- 4) Attorney General’s Model Rules of Procedure **#C4** *Action Necessary*
- 5) Review and affirm Board Per Diem Policy **#C5** *Action Necessary*

Lunch – estimated time depending on the length of discussions

VIII. ISSUES/ACTIVITIES

A. Board Meeting Dates

- | | | |
|------------------------|----------|--|
| • June 5-6, 2019 | Portland | |
| • August 7-9, 2019* | Portland | (*3 day meeting) |
| • October 2-3, 2019 | Portland | |
| • November 6-7, 2019 | Portland | (Strategic Planning – subject to change) |
| • December 11-12, 2019 | Portland | |
| • February 5-7, 2020* | Portland | (*3 day meeting) |
| • April 15-16, 2020 | Portland | |
| • June 17-18, 2020 | Portland | |
| • August 12-14, 2020* | Portland | (*3 day meeting) |

- October 14-15, 2020 Portland
- November 18-19, 2020 TBA (*Strategic Planning – subject to change*)
- December 16-17, 2020 Portland

B. Rulemaking Hearing Dates

(The following dates are reserved for potential rulemaking hearings and identified only for planning purposes and approved by the Board. Actual Rulemaking Activities will be noticed as required by law and may deviate from this schedule as needed.)

- May 22, 2019
- July 23, 2019 (possible)
- September 24, 2019 (possible)
- November 26, 2019

C. Committees/Meetings

1. OSPA Lane Co. Mid-Winter CE Seminar, Eugene – 2/16-17/2019 –
Karbowicz/Logan/Efremoff
2. OSHP Spring Meeting – Sunriver - 4/26-28/2019 – *Schnabel/Efremoff*
3. Linn-Benton Pharmacist Association 4/16/19 - *Baldwin/Linares*
4. NABP 2019 Annual meeting – Minneapolis, MN - May 16-18, 2019
 - a. Resolution review and input **#D CONFIDENTIAL** *Action Necessary*
5. NABP District VI-VIII Mtg. Boise, ID, 10/6-9/2019

D. Board Member/Staff Presentations – *DeBarmore*

- Pharmacy Coalition – 2/12/19, 3/12/19
- Professional Practice Roundtable – none

E. Financial/Budget Report – **#E** *Schnabel/MacLean*

F. Legislative update – *Schnabel/Karbowicz/MacLean*

G. Reports:

1. Board President/Members
2. Executive Director
3. Board Counsel
4. Compliance Director
5. Pharmacist Consultant
6. Administrative Director
7. Licensing Program Supervisor

VIII. Approve Consent Agenda*

Action Necessary

*Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion. If separate discussion is desired, that item will be removed from the consent agenda and placed on the regular business agenda.

1. NAPLEX Scores – 9/1/18 – 12/31/18 **# CONSENT -1 CONFIDENTIAL**
2. MPJE Scores – 9/1/18 – 12/31/18 **# CONSENT -1 CONFIDENTIAL**
3. License/Registration Ratification – January 23, 2019 – March 25, 2019
CONSENT – 2
4. Pharmacy Technician Extensions – none
5. Board Minutes – February 6-7, 2019 **# CONSENT –**

IX. OPEN FORUM – *At the completion of regular Board business, the Board provides an opportunity to make comments or present issues of general interest. The Board will not deliberate any issues or requests during Open Forum. Therefore, Open Forum should not be used to make formal requests to the Board, nor to address issues currently under investigation or requests pending before the Board. If you wish to be called upon, please sign up on the sheet at the podium in advance for inclusion.*

Adjourn



Oregon

Kate Brown, Governor

2019 APRIL / #A

Oregon Board of Pharmacy
800 NE Oregon Street, Suite 150
Portland, OR 97232
Phone: 971 / 673-0001
Fax: 971 / 673-0002
E-mail: pharmacy.board@state.or.us
Web: www.pharmacy.state.or.us

November 13, 2018

NOTICE TO LICENSEES – PROPOSED FEE INCREASES

The Oregon Board of Pharmacy has prepared its 2019-2021 Agency Budget Request for the Governor and Legislative approval during the 2019 Legislative Session. This is available on the Board's "[About Us](#)" web page. Proposed fee increases are necessary to allow the Board to continue current and anticipated operations to carry out the Board's mission.

The agency operates solely on licensing and miscellaneous fees. The Board takes raising fees very seriously and we do all we can to minimize expenses. The last meaningful fee increase was in 2001. In 2011, the Board increased a number of fees, however most were reverted back to the 2001 fees in 2013 due to an unexpected surplus of funds.

The Board's proposed fee increases must be approved by the Governor and Legislature. If authorized, the Board plans to adopt all updated fees by rule. The Board proposes the following fee increases to be effective July 1, 2019 for all new applicants and renewing licensees / registrants. Please see the [chart on the next page](#).

LICENSE CATEGORY	2001 Fees	2017-19 Current Fees	2019-21 Proposed Fees
ANIMAL EUTHANASIA	\$25	\$50	\$75
CERTIFIED PHARMACY TECHNICIAN - *2 yr license	\$35	\$50	\$100
CHARITABLE PHARMACY	\$75	\$75	\$75
COMMUNITY HEALTH CLINIC (previously known as County Health and Family Planning Clinics)	\$75	\$75	\$100
CONSULTING / DRUGLESS PHARMACY	\$175	\$175	\$225
CONTROLLED SUBSTANCE	\$25 or 50	\$50	\$100
DISPENSING PRACTITIONER DRUG OUTLET		\$100	\$100
DRUG DISTRIBUTION AGENT		\$400	\$400
DRUG ROOM & CORRECTIONAL FACILITIES	\$75	\$75	\$100
GASES-MEDICAL CLASS C	\$50	\$50	\$75
INSTITUTIONAL PHARMACY	\$175	\$175	\$225
INTERN LICENSE - 2 yr license	\$30	\$50	\$100
MANUFACTURER	\$400	\$400	\$525
NONPRESCRIPTION A	\$50	\$50	\$75
NONPRESCRIPTION B	\$25	\$50	\$75
NONPRESCRIPTION D	\$100	\$100	\$100
PHARMACIST LICENSE - *2 yr license	\$120	\$120	\$250
PRECURSOR	\$25	\$50	\$75
PROPHYLACTIC CONTRACEPTIVE MGF	\$50	\$50	\$50
REMOTE DISPENSING/DISTRIBUTION		\$100	\$120
RETAIL PHARMACY, includes HOME DIALYSIS	\$175	\$175	\$225
SUPERVISING PHYSICIAN DISPENSING OUTLET		\$175	\$175
PHARMACY TECHNICIAN - *up to 2 yr license	\$35	\$50	\$100
WHOLESALE I, II, III	\$400	\$400	\$525

*Additional background information for items marked with an asterisk for Pharmacists, Certified Oregon Pharmacy Technicians and Pharmacy Technicians were converted to a two-year biennial license between 2015 and 2016 without a fee increase; in other words, licensees received a two-year license for the price of a one-year license. The noted increases update the annual fee to a biennial fee (ORS 183.705).

SBAR: Retail Sales of Cannabidiol (CBD) Products and Pharmacies

S	<p>Situation:</p> <p>Compliance staff are receiving questions about CBD sales, such as:</p> <ul style="list-style-type: none"> • Are pharmacies permitted to sell CBD products at the retail (front-end) of the store and if so does this require registration with a regulatory body? • Who regulates these products and verifies that the amount of THC is within legal concentrations, per 2018 Farm Bill THC level < 0.3%? • Are there any restrictions to sale; age restriction, limit in quantity, delivery mechanism? • Can CBD products be sold at the pharmacy register? • Who may answer questions about CBD? • May CBD be sold as a dietary supplement? 												
B	<p>Background:</p> <ul style="list-style-type: none"> • 2018 Farm Bill legalized industrial hemp (THC <0.3%). • 2018 OR SB 1544 require that products sold in an Oregon Liquor Control Commission (OLCC) retailer (recreational marijuana) must have a label that clearly identifies the source of CBD: hemp vs. marijuana. • 2018 OR HB 4089 states marijuana products are subject to regulation by OLCC & Oregon Health Authority (OHA). Industrial hemp products are subject to regulation by Oregon Department of Agriculture (ODA). • FDA states if a substance has an active ingredient in a drug product (i.e. CBD in Epidiolex), then products containing that substance cannot be defined as a supplement. • DEA stated that most CBD depending on the source, when extracted from Cannabis sativa, was a Schedule I substance: <table border="1" data-bbox="289 1020 1417 1488"> <thead> <tr> <th>Source of CBD</th> <th>Controlled?</th> </tr> </thead> <tbody> <tr> <td>Marijuana (i.e. <i>Cannabis sativa</i> containing >0.3% THC)</td> <td>Yes. Marijuana is a Schedule I controlled substance.</td> </tr> <tr> <td>Hemp</td> <td>No. The 2018 Farm Bill removed hemp and its extracts from the Controlled Substances schedules.</td> </tr> <tr> <td>Mature stalks or sterilized seeds of marijuana</td> <td>No. However, according to the DEA, these parts of the plant only contain trace amounts of CBD.</td> </tr> <tr> <td>Epidiolex</td> <td>Yes. FDA-approved drugs containing CBD are Schedule V controlled substances.</td> </tr> <tr> <td>Non-cannabis sources (includes botanicals like hop plants, evergreens, & lemon peels)</td> <td>No.</td> </tr> </tbody> </table>	Source of CBD	Controlled?	Marijuana (i.e. <i>Cannabis sativa</i> containing >0.3% THC)	Yes. Marijuana is a Schedule I controlled substance.	Hemp	No. The 2018 Farm Bill removed hemp and its extracts from the Controlled Substances schedules.	Mature stalks or sterilized seeds of marijuana	No. However, according to the DEA, these parts of the plant only contain trace amounts of CBD.	Epidiolex	Yes. FDA-approved drugs containing CBD are Schedule V controlled substances.	Non-cannabis sources (includes botanicals like hop plants, evergreens, & lemon peels)	No.
Source of CBD	Controlled?												
Marijuana (i.e. <i>Cannabis sativa</i> containing >0.3% THC)	Yes. Marijuana is a Schedule I controlled substance.												
Hemp	No. The 2018 Farm Bill removed hemp and its extracts from the Controlled Substances schedules.												
Mature stalks or sterilized seeds of marijuana	No. However, according to the DEA, these parts of the plant only contain trace amounts of CBD.												
Epidiolex	Yes. FDA-approved drugs containing CBD are Schedule V controlled substances.												
Non-cannabis sources (includes botanicals like hop plants, evergreens, & lemon peels)	No.												
A	<p>Assessment:</p> <p>Given that the 2018 Farm Bill legalized hemp (including its extracted products like CBD), it is legal to sell these products so long as they are not advertised as a dietary supplement, also provided that the THC concentration is <0.3%. Testing requirements are implemented and enforced by ODA to make sure growers and processors are in compliance prior to sale or transfer to consumers. Currently they do not require a license or registration for businesses to sell CBD products under the hemp program. There are no age restriction or limitation on purchases from retail locations.</p>												
R	<p>Recommendation:</p> <p>NPA (nonprescription drug) outlets may sell CBD products at the retail store without a license/registration from the ODA, as long as the product has below 0.3% THC and it is not</p>												

	advertised as a dietary supplement. CBD sales may occur at the pharmacy register by any staff, but all questions related to CBD products should be directed to the pharmacist. CBD products should not be stored in the pharmacy or ordered through the pharmacy.
--	---

Date: 3/21/19

Author: OBOP Staff

SBAR: Pharmacist Continuing Education Requirements for Renewal

<p>S</p>	<p>Situation:</p> <p>It was noted at the Board Meeting on February 7, 2019 that we planned to use the revised policy that was used for the CPT renewal, which does not require CE to be completed prior to renewal but requires them to attest to the fact that it will be completed prior to license expiration.</p> <p>In preparation for the RPh renewal and possible notification to licensed Pharmacists regarding the policy revision, it was discovered that OAR 855-021-0005(1) prohibits the use of the policy for the upcoming renewal cycle.</p> <p>The Board was notified on March 4th that we are unable to use the policy for the upcoming pharmacist renewal. Notification was not sent out, so the messaging regarding the CE requirements for this renewal cycle is not different than previous renewal cycles.</p> <p>Staff is unsure of the scope of notification that may have been made via word of mouth from the conversation on February 7th.</p>
<p>B</p>	<p>Background:</p> <p>Certified Oregon Pharmacy Technician rules <u>do not</u> specify that the CE has to be completed <i>prior to renewal</i>, so the language used in the renewal to say "have completed or will have completed by June 30, 2018" was acceptable, via policy decision.</p> <p>Applicable RPH rules were changed in 2015 to include new language specific to the completion of CE prior to renewal:</p> <p>855-021-0005(1) During the period from July 1 through June 30 of each biennial license renewal cycle, each pharmacist must have satisfactorily completed three (3) continuing pharmacy education units (CEU's) in an approved continuing pharmacy education program prior to submission of the license renewal. Ten contact hours equals 1 CEU. Fifty minutes equals 1 contact hour.</p> <p>855-021-0050(1) The biennial renewal application must be submitted to the Board with the appropriate fee and the pharmacist must attest that he/she has satisfactorily completed the continuing pharmacy education requirements."</p> <p>We will not be able to use the language used in the CPT renewal because it would be a violation of the rules.</p> <p>Additionally, this has been previously addressed by the Board in the Staff delegated authority, which allows the Compliance staff to issue Letter of Concern for CE not completed in the required timeframe.</p>

	<table border="1"> <tr> <td>RPH renewals: CE Audits</td> <td colspan="4">CE not completed or completed outside of required timeframe</td> </tr> <tr> <td></td> <td>• Non-responder</td> <td>Revoke and \$1,000 civil penalty per violation</td> <td>Revoke</td> <td>Case Review</td> </tr> <tr> <td></td> <td>• Discipline</td> <td>\$1,000 civil penalty per violation</td> <td>\$1,000 stay \$0 - \$1,000 and provide documentation of CE licensee was short</td> <td>Case Review</td> </tr> <tr> <td></td> <td>• Completed after renewal but before license expired</td> <td colspan="2">Issue Letter of Concern</td> <td>Consent Agenda</td> </tr> </table>	RPH renewals: CE Audits	CE not completed or completed outside of required timeframe					• Non-responder	Revoke and \$1,000 civil penalty per violation	Revoke	Case Review		• Discipline	\$1,000 civil penalty per violation	\$1,000 stay \$0 - \$1,000 and provide documentation of CE licensee was short	Case Review		• Completed after renewal but before license expired	Issue Letter of Concern		Consent Agenda
RPH renewals: CE Audits	CE not completed or completed outside of required timeframe																				
	• Non-responder	Revoke and \$1,000 civil penalty per violation	Revoke	Case Review																	
	• Discipline	\$1,000 civil penalty per violation	\$1,000 stay \$0 - \$1,000 and provide documentation of CE licensee was short	Case Review																	
	• Completed after renewal but before license expired	Issue Letter of Concern		Consent Agenda																	
A	<p>Assessment:</p> <p>The notification was not made to the general public. Because of this, we believe there were only a small number of people who were aware of the intention to use the revised policy.</p> <p>The staff discussed the policy vs. rule with Board Counsel. Determination was made not to recommend a rule change at this time. The Board added this rule language in 2015 and the rules demonstrate the threshold of accountability for the professionals licensed by the Board.</p>																				
R	<p>Recommendations:</p> <ul style="list-style-type: none"> Take no action. Messaging from previous renewal cycles (renewal notice, FAQ's, renewal questions) included the requirement to have completed CE prior to renewal. No changes are proposed for current renewal cycle and will be consistent with last renewal and rule compliance. 																				

Date: 3/29/19

Author: Chrisy Hennigan

Copy of 2019-2021 Renewal postcard:



**OREGON BOARD OF PHARMACY
PHARMACIST RENEWAL AVAILABLE
ONLINE NOW!**

Your Pharmacist License will expire on June 30, 2019. The online renewal is available now on the Oregon Board of Pharmacy's website.

The fee to renew your biennial license by May 31st is \$174.00. The fee to renew your license on June 1st or later is \$224.00.

www.oregon.gov/pharmacy

You will also find FAQs about renewing your license, CE requirements and other helpful links.

To save \$50.00, please complete the required CE and renew your license before June 1st!

**OREGON BOARD OF PHARMACY
2019 PHARMACIST CONTINUING EDUCATION
FREQUENTLY ASKED QUESTIONS (FAQ'S)**

Every two years, Oregon Pharmacists must complete 30 hours of Continuing Education (CE) to consist of at least 2 hours of pharmacy and drug law, 2 hours of safety/error prevention and 26 'other' (therapeutics, etc.) hours. Eligible hours for the 2019 renewal cycle must be completed in the period of July 1, 2017 - June 30, 2019.

1. **Q. I recently obtained my Pharmacist license in Oregon. Do I have to complete the required CE prior to renewing my license this year?**
A. It depends on your initial issue date on your license.
 - *If you were initially licensed from July 1, 2017 - June 30, 2018, **YES**, you **MUST** complete the continuing education requirements prior to renewing your license.*
 - *If you were initially licensed from July 1, 2018 – June 30, 2019, **NO**, you **DO NOT** have to complete the continuing education requirements for this license renewal.*

2. **Q. I completed the required 7 hours of Pain Management CE last year, am I required to complete Pain Management CE again?**
A. No. All Pharmacists are required to have completed a one-time requirement of Pain Management CE within 24 months of their first license renewal. If 2019 is your first renewal, the pain management CE must be completed in the period of July 1, 2017 – June 30, 2021.

3. **Q. Where can I obtain Pain CE?**
A. One of the seven hours of Pain Management CE must be earned from the Oregon Pain Management Commission. This one hour mandatory Pain Management CE module can be found on their website:
<http://www.oregon.gov/oha/ohpr/pmc/pages/index.aspx>

4. **Q. Where can I find information regarding Pain Management CE?**
A. The Oregon Pain Management Commission (OPMC) offers the required Pain module. It can be found at:
<http://www.oregon.gov/oha/ohpr/pmc/pages/index.aspx>.

The OPMC strongly recommends that a component of the additional 6 hours of continuing education include the new understanding of the neuroscience and the complex biopsychosocial nature of pain in addition to the International Association for the Study of Pain (IASP) Guidelines and Center for Disease Control (CDC) Opioid Prescribing Guidelines.

5. **Q. I have until June 30, 2019 to complete my CE but the fee is higher if I renew my license after May 31, 2019. What can I do to avoid paying the additional fee?**
A. The only way to avoid paying the higher fee is to renew your license by May 31, 2019. This means that you must complete the required CE and renew your license by May 31, 2019.

6. **Q.** During the renewal cycle, do I have to submit copies of my completed CE to the Oregon Board of Pharmacy?
A. No. Please do not forward copies of your CE certificates to the Board unless you receive notification that you have been selected for a CE Audit.
7. **Q.** How do I know if I have been selected for a CE Audit?
A. If you are selected for a CE Audit, you will receive a notification in August 2019, which will require you to provide your CE certificates to the Board pursuant to OAR 855-021-0050(2). You will have approximately one month to provide the Board with copies of your CE certificates.
8. **Q.** I plan to renew my license after the expiration date of June 30, 2019. Will my CE be audited?
A. Yes, all Pharmacists who submit a renewal after the license expiration date will be automatically required to complete a CE Audit. Please email the documentation of your CE to: pharmacy.audit@oregon.gov.
9. **Q.** Does the Board require "Live" CE?
A. At this time, there is no requirement to have attended a "Live" CE session.
10. **Q.** I don't have my CE certificates because I track my CE another way. What do I do?
A. If you obtain your Continuing Education through Pharmacists Letter or use the NABP CE Monitoring program to track your CE, you can submit the **PDF transcript** of completed CE to pharmacy.audit@oregon.gov. Downloaded excel spreadsheets will not be accepted.

You do not have to submit each individual certificate if you track your CE this way.
11. **Q.** I have been selected for audit but cannot find copies of my completed CE. What should I do?
A. Please contact the CE provider for proof of completion, as they are required to keep completed CE on file for at least three years.
12. **Q.** I renewed my license and attested to the fact that my CE was completed, but I did not have all of my CE completed prior to renewing my license, or I cannot provide proof of completion. What happens next?
A. Your audit materials will be presented to the Compliance Department for further review and may need to be presented to the Board for disciplinary consideration at an upcoming Board Meeting.
13. **Q.** How long should I retain the proof of my CE?
B. You should retain the proof of CE for three years.

2019 Accreditation Council for Pharmacy Education (ACPE) & Continuing Pharmacy Education (CPE or CE) Review

During the Board's Annual Business Meeting, the Board reviews and approves a list of the ACPE Accredited Professional Programs of Colleges and Schools of Pharmacy as well as the ACPE Continuing Education Process guidelines, policies and procedures.

The following are links from the ACPE website and the most efficient way to provide it for your review.

For **ACPE Accredited Professional Programs of Colleges and Schools of Pharmacy**, please click here: <https://www.acpe-accredit.org/pharmd-program-accreditation/>. Towards the bottom of this web page is a link to *Programs by Status* and *Programs by State* and then you can click from there to review the Accredited / Candidate status or Pre-candidate status categories.

- 1) For **ACPE Policies and Procedures for ACPE Accreditation of Professional Degree Programs**, effective January 2019, click here: https://www.acpe-accredit.org/pdf/CS_PoliciesandProcedures.pdf

Main Continuing Education Provider Accreditation page: <https://www.acpe-accredit.org/continuing-education-provider-accreditation/>

Here are the things the Board usually reviews annually related to Continuing Education:

- 2) For ACPE **Guidelines associated with the ACPE Definition of CE for the Profession of Pharmacy**, effective January 2018, click here: https://www.acpe-accredit.org/pdf/CPE_Standards_Final.pdf
- 3) For ACPE: **Definition of Continuing Education for the Profession of Pharmacy** <https://www.acpe-accredit.org/pdf/DefinitionofCE.pdf>
- 4) For **ACPE Continuing Pharmacy Education Provider Accreditation Program Policies and Procedures Manual: A Guide for ACPE accredited Providers**, effective January 1, 2009, updated July 2017 click here: https://www.acpe-accredit.org/pdf/CPE_Policies_Procedures.pdf

CONTROLLED SUBSTANCES

- ALPHABETICAL ORDER -

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
6-bromo-androsta-1,4-diene-3,17-dione	4000	III	N	
[3,2-c]-furazan-5 α -androstan-17 β -ol	4000	III	N	
[3,2-c]pyrazole-androst-4-en-17 β -ol	4000	III	N	
1-(1-Phenylcyclohexyl)pyrrolidine	7458	I	N	PCPy, PHP, rolicyclidine
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	9663	I	Y	PEPAP, synthetic heroin
1-[1-(2-Thienyl)cyclohexyl]piperidine	7470	I	N	TCP, tenocyclidine
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	7473	I	N	TCPy
13Beta-ethyl-17beta-hydroxygon-4-en-3-one	4000	III	N	
17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane	4000	III	N	
17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane	4000	III	N	
17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene	4000	III	N	
17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one)	4000	III	N	
17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)	4000	III	N	17-Alpha-methyl-1-testosterone
17 α -Methyl-5 α -androstan-17 β -ol	4000	III	N	
17 α -methyl-androst-2-ene-3,17 β -diol	4000	III	N	
17 α -methyl-androsta-1,4-diene-3,17 β -diol	4000	III	N	
17 α -Methyl-androstan-3-hydroxyimine-17 β -ol	4000	III	N	
17 β -Hydroxy-androstano[2,3-d]isoxazole	4000	III	N	
17 β -Hydroxy-androstano[3,2-c]isoxazole	4000	III	N	
18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one	4000	III	N	
19-Nor-4,9(10)-androstadienedione	4000	III	N	
19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 3alpha,17beta-dihydroxyestr-4-ene)	4000	III	N	
19-Nor-4-androstenedione (estr-4-en-3,17-dione)	4000	III	N	
19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 3alpha,17beta-dihydroxyestr-5-ene)	4000	III	N	
19-Nor-5-androstenedione (estr-5-en-3,17-dione)	4000	III	N	
1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene; 3alpha,17beta-dihydroxy-5alpha-androst-1-ene)	4000	III	N	
1-Androstenedione (5alpha-androst-1-en-3,17-dione)	4000	III	N	
1-Methyl-4-phenyl-4-propionoxypiperidine	9661	I	Y	MPPP, synthetic heroin

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
1-Phenylcyclohexylamine	7460	II	N	PCP precursor
1-Piperidinocyclohexanecarbonitrile	8603	II	N	PCC, PCP precursor
2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	I	N	2C-P
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E)	7509	I	N	2C-E (Positional Isomer: 2,5-Dimethoxy-3,4-dimethylphenethylamine (2C-G))
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	I	N	2C-D
2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N)	7521	I	N	2C-N
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	I	N	2C-H
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe)	7536	I	N	25B-NBOMe, 2C-B-NBOMe, 25B, Cimbi-36
2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	I	N	2C-C
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)	7537	I	N	25C-NBOMe, 2C-C-NBOMe, 25C, Cimbi-82
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2)	7385	I	N	2C-T-2
2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)	7518	I	N	2C-I
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)	7538	I	N	25I-NBOMe, 2C-I-NBOMe, 25I, Cimbi-5
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4)	7532	I	N	2C-T-4 (Positional Isomer: 2,5-Dimethoxy-4-ethylthioamphetamine (Aleph-2))
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)	7348	I	N	2C-T-7 (Positional Isomer: 2,5-Dimethoxy-4-ethylthioamphetamine (Aleph-2))
2,5-Dimethoxy-4-ethylamphetamine	7399	I	N	DOET
2,5-Dimethoxyamphetamine	7396	I	N	DMA, 2,5-DMA
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide	9825	I	Y	Methoxyacetyl fentanyl
2 α ,17 α -dimethyl-17 β -hydroxy-5 β -androstane-3-one	4000	III	N	
2 α ,3 α -epithio-17 α -methyl-5 α -androstane-17 β -ol	4000	III	N	
3,4,5-Trimethoxyamphetamine	7390	I	N	TMA (Positional Isomers: 2,4,5-Trimethoxyamphetamine (TMA-5), 2,4,6-Trimethoxyamphetamine (TMA-6), Escaline)
3,4-Methylenedioxyamphetamine	7400	I	N	MDA, Love Drug
3,4-Methylenedioxymethamphetamine	7405	I	N	MDMA, Ecstasy, XTC
3,4-Methylenedioxy-N-ethylamphetamine	7404	I	N	N-ethyl MDA, MDE, MDEA
3Alpha,17beta-dihydroxy-5alpha-androstane	4000	III	N	
3Beta,17beta-dihydroxy-5alpha-androstane	4000	III	N	
3-Fluoro-N-methylcathinone (3-FMC)	1233	I	N	1-(3-fluorophenyl)-2-(methylamino)propan-1-one (Positional isomer: 2-FMC)
3-Methylfentanyl	9813	I	Y	China White, fentanyl
3-Methylthiofentanyl	9833	I	Y	China White, fentanyl
3 β -hydroxy-estra-4,9,11-trien-17-one	4000	III	N	

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
4-Androstenediol (3beta,17beta-dihydroxy-androst-4-ene)	4000	III	N	4-AD
4-Androstenedione (androst-4-en-3,17-dione)	4000	III	N	
4-Anilino-N-phenethyl-4-piperidine (ANPP)	8333	II	N	ANPP, Despropionyl fentanyl
4-Bromo-2,5-dimethoxyamphetamine	7391	I	N	DOB, 4-bromo-DMA
4-Bromo-2,5-dimethoxyphenethylamine	7392	I	N	2C-B, Nexus, has been sold as Ecstasy, i.e. MDMA
4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-en-3-one	4000	III	N	
4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-ene-3,11-dione	4000	III	N	
4-chloro-17alpha-methyl-androst-4-ene-3beta,17beta-diol	4000	III	N	
4-chloro-17alpha-methyl-androsta-1,4-diene-3,17beta-diol	4000	III	N	
4-CN-CUMYL-BUTINACA (1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide)	7089	I	N	4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78
4-Dihydrotestosterone (17beta-hydroxyandrost-3-one)	4000	III	N	Anabolex, Andractim, Pesomax, Stanolone
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)	9824	I	Y	Para-fluoroisobutyryl fentanyl
4-Fluoro-N-methylcathinone (4-FMC)	1238	I	N	flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one) (Positional isomer: 2-FMC)
4-Hydroxy-19-nortestosterone (4,17beta-dihydroxyestr-4-en-3-one)	4000	III	N	
4-Hydroxy-androst-4-ene-3,17-dione	4000	III	N	Listed as 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5alpha-androstan-17beta-ol
4-Hydroxytestosterone (4,17beta-dihydroxyandrost-4-en-3-one)	4000	III	N	
4-Methoxyamphetamine	7411	I	N	PMA
4-Methyl-2,5-dimethoxyamphetamine	7395	I	N	DOM, STP (Positional Isomer: 2,5-Dimethoxy-3,4-dimethylphenethylamine (2C-G))
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)	7498	I	N	MePPP, 4-methyl-alpha-pyrrolidinopropiophenone, 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one)
4-Methylaminorex (cis isomer)	1590	I	N	U4Euh, McN-422
4-Methyl-N-ethylcathinone (4-MEC)	1249	I	N	2-(ethylamino)-1-(4-methylphenyl)propan-1-one)(Positional Isomers:3-methylethcathinone (3-MEC), 4-ethylmethcathinone (4-EMC), 4-methylbuphedrone (4-MeMABP;4-MeBP), 3,4-dimethylmethcathinone(3,4-DMMC),N-ethylbuphedrone (NEB),N-ethyl-N-methylcathinone(EMC))
5-Androstenediol (3beta,17beta-dihydroxy-androst-5-ene)	4000	III	N	
5-Androstenedione (androst-5-en-3,17-dione)	4000	III	N	
5F-AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1 H-indazole-3-carboxamide)	7025	I	N	

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
5F-ADB; 5F-MDMB-PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7034	I	N	5F-ADB, 5F-MDMB-PINACA
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)	7033	I	N	5F-AMB
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)	7049	I	N	5F-APINACA, 5F-AKB48
5F-CUMYL-P7AICA (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-carboxamide)	7085	I	N	
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	7011	I	N	5-Fluoro-UR-144, XLR-11 and XLR11
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate)	7225	I	N	5-Fluoro-PB-22; 5F-PB-22
5-Methoxy-3,4-methylenedioxyamphetamine	7401	I	N	MMDA
5-Methoxy-N,N-diisopropyltryptamine	7439	I	N	5-MeO-DIPT (Positional Isomer: 5-Methoxy-N,N-dipropyltryptamine (5-MeO-DPT))
5-Methoxy-N,N-dimethyltryptamine	7431	I	N	5-MeO-DMT (Positional Isomer: 4-Methoxy-N,N-dimethyltryptamine (4-MeO-DMT))
5α-Androstan-3,6,17-trione	4000	III	N	
6-bromo-androstan-3,17-dione	4000	III	N	
6α-Methyl-androst-4-ene-3,17-dione	4000	III	N	
AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7031	I	N	AB-CHMINACA
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7012	I	N	AB-FUBINACA
AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7023	I	N	AB-PINACA
Acetorphine	9319	I	Y	
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9821	I	Y	
Acetyl-alpha-methylfentanyl	9815	I	Y	
Acetyldihydrocodeine	9051	I	Y	Acetylcodeine
Acetylmethadol	9601	I	Y	Methadyl acetate
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide)	9811	I	Y	Acryloylfentanyl
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7010	I	N	ADB-FUBINACA
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7035	I	N	ADB-PINACA
AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide))	9551	I	Y	AH-7921
Alfaxalone	2731	IV	N	Alfaxan, 5α-pregnan-3α-ol-11,20-dione
Alfentanil	9737	II	Y	Alfenta

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Allylprodine	9602	I	Y	
Alphacetylmethadol except levo-alphacetylmethadol	9603	I	Y	
Alpha-ethyltryptamine	7249	I	N	ET, Trip
Alphameprodine	9604	I	Y	
Alphamethadol	9605	I	Y	
Alpha-methylfentanyl	9814	I	Y	China White, fentanyl
Alpha-methylthiofentanyl	9832	I	Y	China White, fentanyl
Alpha-methyltryptamine	7432	I	N	AMT (Positional Isomer: N-Methyltryptamine)
Alphaprodine	9010	II	Y	Nisentil
alpha-pyrrolidinobutiophenone (α-PBP)	7546	I	N	1-phenyl-2-(pyrrolidin-1-yl)butan-1-one
alpha-pyrrolidinopentiophenone (α-PVP)	7545	I	N	α-pyrrolidinovalerophenone, 1-phenyl-2- (pyrrolidin-1-yl)pentan-1-one)(Positional isomers: 4-methyl-α-pyrrolidinobutiophenone (4-MePBP), 1-phenyl-2-(piperidin-1-yl)butan-1-one)
Alprazolam	2882	IV	N	Xanax
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole)	7201	I	N	AM2201
AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole)	7694	I	N	AM-694
Aminorex	1585	I	N	has been sold as methamphetamine
Amobarbital	2125	II	N	Amytal, Tuinal
Amobarbital & noncontrolled active ingred.	2126	III	N	
Amobarbital suppository dosage form	2126	III	N	
Amphetamine	1100	II	N	Dexedrine, Adderall, Obetrol
Anabolic steroids	4000	III	N	"Body Building" drugs
Androstenedione (5alpha-androstan-3,17-dione)	4000	III	N	
Anileridine	9020	II	Y	Leritine
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide	7048	I	N	APINACA and AKB48
Approved Cannabidiol Drugs (as defined in 21 CFR 1308.15(f))	7367	V	N	A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains Cannabidiol derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
Aprobarbital	2100	III	N	Alurate
Barbital	2145	IV	N	Veronal, Plexonal, barbitone
Barbituric acid derivative	2100	III	N	Barbiturates not specifically listed
Benzethidine	9606	I	Y	
Benzphetamine	1228	III	N	Didrex, Inapetyl
Benzylmorphine	9052	I	Y	
Betacetylmethadol	9607	I	Y	
Beta-hydroxy-3-methylfentanyl	9831	I	Y	China White, fentanyl

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Beta-hydroxyfentanyl	9830	I	Y	China White, fentanyl
Beta-hydroxythiofentanyl	9836	I	Y	N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide, N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide
Betameprodine	9608	I	Y	
Betamethadol	9609	I	Y	
Betaprodine	9611	I	Y	
Bezitramide	9800	II	Y	Burgodin
Bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	
Boldenone (17beta-hydroxyandrost-1,4-diene-3-one)	4000	III	N	Equipoise, Parenabol, Vebonol, dehydrotestosterone
Boldione	4000	III	N	
Brivaracetam	2710	V	N	BRV, UCB-34714, Briviact, ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide)
Bromazepam	2748	IV	N	Lexotan, Lexatin, Lexotanol
Bufotenine	7433	I	N	Mappine, N,N-dimethylserotonin
Buprenorphine	9064	III	Y	Buprenex, Temgesic, Subutex, Suboxone
Butabarbital (secbutabarbital)	2100	III	N	Butisol, Butibel
Butalbital	2100	III	N	Fiorinal, Butalbital with aspirin
Butobarbital (butethal)	2100	III	N	Soneryl (UK)
Butorphanol	9720	IV	N	Stadol, Stadol NS, Torbugesic, Torbutrol
Butylone	7541	I	N	bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (Positional Isomers: ethylone (bk-MDEA; MDEC), dimethylone (bk-MDDMA; MDDMC))
Butyryl Fentanyl	9822	I	Y	N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide
Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Methosarb
Camazepam	2749	IV	N	Albego, Limpidon, Paxor
Carfentanyl	9743	II	Y	Wildnil
Carisoprodol	8192	IV	N	Soma
Cathine	1230	IV	N	Constituent of "Khat" plant, (+)-norpseudoephedrine
Cathinone	1235	I	N	Constituent of "Khat" plant
Chloral betaine	2460	IV	N	Beta Chlor
Chloral hydrate	2465	IV	N	Noctec
Chlordiazepoxide	2744	IV	N	Librium, Libritabs, Limbitrol, SK-Lygen
Chlorhexadol	2510	III	N	Mechloral, Mecoral, Medodorm, Chloralodol
Chlorphentermine	1645	III	N	Pre-Sate, Lucofen, Apsedon, Desopimon
Clobazam	2751	IV	N	Urbadan, Urbanyl
Clonazepam	2737	IV	N	Klonopin, Clonopin

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Clonitazene	9612	I	Y	
Clorazepate	2768	IV	N	Tranxene
Clortermine	1647	III	N	Voranil
Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Alfa-Trofodermin, Clostene, 4-chlorotestosterone
Clotiazepam	2752	IV	N	Trecalmo, Rize, Clozan, Veratran
Cloxazolam	2753	IV	N	Akton, Lubalix, Olcadil, Sepazon
Coca Leaves	9040	II	Y	
Cocaine	9041	II	Y	Methyl benzoylcegonine, Crack
Codeine	9050	II	Y	Morphine methyl ester, methyl morphine
Codeine & isoquinoline alkaloid 90 mg/du	9803	III	Y	Codeine with papaverine or noscapine
Codeine combination product 90 mg/du	9804	III	Y	Empirin, Fiorinal, Tylenol, ASA or APAP w/codeine
Codeine methylbromide	9070	I	Y	
Codeine preparations - 200 mg/(100 ml or 100 gm)		V	Y	Cosanyl, Robitussin A-C, Cheracol, Cerose, Pediacof
Codeine-N-oxide	9053	I	Y	
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol)	7297	I	N	CP-47,497
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol)	7298	I	N	CP-47,497 C8 Homologue
Cyclopentyl fentanyl	9847	I	Y	N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide
Cyclopropyl Fentanyl	9845	I	Y	N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide
Cyprenorphine	9054	I	Y	
Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one)	4000	III	N	Oral-Turinabol
Delorazepam	2754	IV	N	
Delta1-dihydrotestosterone (17beta-hydroxy-5alpha-androst-1-en-3-one)	4000	III	N	1-Testosterone
Desomorphine	9055	I	Y	
Desoxymethyltestosterone	4000	III	N	
Dexfenfluramine	1670	IV	N	Redux
Dextromoramide	9613	I	Y	Palfium, Jetrium, Narcolo
Dextropropoxyphene dosage forms	9278	IV	Y	Darvon, propoxyphene, Darvocet, Propacet
Dextropropoxyphene, bulk (non-dosage forms)	9273	II	Y	Propoxyphene
Diampromide	9615	I	Y	
Diazepam	2765	IV	N	Valium, Diastat
Dichloralphenazone	2467	IV	N	Midrin, dichloralantipyrene
Diethylpropion	1610	IV	N	Tenuate, Tepanil
Diethylthiambutene	9616	I	Y	

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Diethyltryptamine	7434	I	N	DET, N,N-Diethyltryptamine (Positional Isomer: N-Methyl-N-isopropyltryptamine (MiPT))
Difenoxin	9168	I	Y	Lyspafen
Difenoxin 1 mg/25 ug AtSO4/du	9167	IV	Y	Motofen
Difenoxin preparations - 0.5 mg/25 ug AtSO4/du		V	Y	Motofen
Dihydrocodeine	9120	II	Y	Didrate, Parzone
Dihydrocodeine combination product 90 mg/du	9807	III	Y	Synalgos-DC, Compal
Dihydrocodeine preparations 100mg/(100 ml or 100 gm)		V	Y	Cophene-S, various others
Dihydroetorphine	9334	II	Y	DHE
Dihydromorphine	9145	I	Y	
Dimenoxadol	9617	I	Y	
Dimepheptanol	9618	I	Y	
Dimethylthiambutene	9619	I	Y	
Dimethyltryptamine	7435	I	N	DMT
Dioxaphetyl butyrate	9621	I	Y	
Diphenoxylate	9170	II	Y	
Diphenoxylate preparations 2.5 mg/25 ug AtSO4		V	Y	Lomotil, Logen
Dipipanone	9622	I	Y	Dipipan, phenylpiperone HCl, Diconal, Wellconal
Dronabinol (synthetic) in sesame oil in soft gelatin capsule as approved by FDA	7369	III	N	Marinol, synthetic THC in sesame oil/soft gelatin as approved by FDA
Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration	7365	II	N	Syndros
Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one)	4000	III	N	Drolban, Masterid, Permastril
Drotebanol	9335	I	Y	Metebanyl, oxymetebanol
Ecgonine	9180	II	Y	Cocaine precursor, in Coca leaves
Eluxadoline	9725	IV	N	VIBERZI
Embutramide	2020	III	N	Tributane
Estazolam	2756	IV	N	ProSom, Domnamid, Eurodin, Nuctalon
Estra-4,9,11-triene-3,17-dione	4000	III	N	
Ethchlorvynol	2540	IV	N	Placidyl
Ethinamate	2545	IV	N	Valmid, Valamin
Ethyl loflazepate	2758	IV	N	
Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene)	4000	III	N	Maxibolin, Orabolin, Durabolin-O, Duraboral
Ethylmethylthiambutene	9623	I	Y	
Ethylmorphine	9190	II	Y	Dionin
Ethylmorphine combination product 15 mg/du	9808	III	Y	

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Ethylmorphine preparations 100 mg/(100 ml or 100 gm)		V	Y	
Etonitazene	9624	I	Y	
Etorphine (except HCl)	9056	I	Y	
Etorphine HCl	9059	II	Y	M 99
Etoxidine	9625	I	Y	
Ezogabine	2779	V	N	Potiga
Fencamfamin	1760	IV	N	Reactivan
Fenethylamine	1503	I	N	Captagon, amfetamine, ethyltheophylline amphetamine
Fenfluramine	1670	IV	N	Pondimin, Ponderal
Fenproporex	1575	IV	N	Gacilin, Solvolip
Fentanyl	9801	II	Y	Duragesic, Oralet, Actiq, Sublimaze, Innovar
Fentanyl related-compounds as defined in 21 CFR 1308.11(h)	9850	I	Y	
Fludiazepam	2759	IV	N	
Flunitrazepam	2763	IV	N	Rohypnol, Narcozep, Darkene, Roipnol
Fluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one)	4000	III	N	Anadroid-F, Halotestin, Ora-Testryl
Flurazepam	2767	IV	N	Dalmane
Formebolone (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-dien-3-one)	4000	III	N	Esiclone, Hubernol
Fospropofol	2138	IV	N	Lusedra
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)	9834	I	Y	
Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan)	4000	III	N	Frazalon, Miotolon, Qu Zhi Shu
Furethidine	9626	I	Y	
Gamma Hydroxybutyric Acid	2010	I	N	GHB, gamma hydroxybutyrate, sodium oxybate
Gamma Hydroxybutyric Acid preparations	2012	III	N	Xyrem
Glutethimide	2550	II	N	Doriden, Dorimide
Halazepam	2762	IV	N	Paxipam
Haloxazolam	2771	IV	N	
Heroin	9200	I	Y	Diacetylmorphine, diamorphine
Hydrocodone	9193	II	Y	dihydrocodeinone
Hydromorphanol	9301	I	Y	
Hydromorphone	9150	II	Y	Dilaudid, dihydromorphinone
Hydroxypethidine	9627	I	Y	
Ibogaine	7260	I	N	Constituent of "Tabernanthe iboga" plant
Isobutyryl fentanyl	9827	I	Y	N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide
Isomethadone	9226	II	Y	Isoamidone

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole)	7118	I	N	JWH-018 and AM-678
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)	7019	I	N	JWH-019
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)	7173	I	N	JWH-073
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole)	7081	I	N	JWH-081
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole)	7122	I	N	JWH-122
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	7200	I	N	JWH-200
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole)	7203	I	N	JWH-203
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole)	6250	I	N	JWH-250
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole)	7398	I	N	JWH-398
Ketamine	7285	III	N	Ketaset, Ketalar, Special K, K
Ketazolam	2772	IV	N	Anxon, Loftran, Solatran, Contamex
Ketobemidone	9628	I	Y	Cliradon
Lacosamide	2746	V	N	Vimpat
Levo-alphaacetylmethadol	9648	II	Y	LAAM, long acting methadone, levomethadyl acetate
Levomethorphan	9210	II	Y	
Levomoramide	9629	I	Y	
Levophenacymorphan	9631	I	Y	
Levorphanol	9220	II	Y	Levo-Dromoran
Lisdexamfetamine	1205	II	N	Vyvanse
Loprazolam	2773	IV	N	
Lorazepam	2885	IV	N	Ativan
Lorcaserin	1625	IV	N	Belviq
Lormetazepam	2774	IV	N	Noctamid
Lysergic acid	7300	III	N	LSD precursor
Lysergic acid amide	7310	III	N	LSD precursor
Lysergic acid diethylamide	7315	I	N	LSD, lysergide
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7032	I	N	MAB-CHMINACA and ADB-CHMINACA
Marihuana	7360	I	N	Cannabis, marijuana
Marihuana Extract	7350	I	N	
Mazindol	1605	IV	N	Sanorex, Mazanor
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)	7042	I	N	MDMB-CHMICA, MMB-CHMINACA
MDMB-FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7020	I	N	MDMB-FUBINACA
MDPV (3,4-Methylenedioxypropylvalerone)	7535	I	N	MDPV

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Mebutamate	2800	IV	N	Capla
Mecloqualone	2572	I	N	Nubarene
Medazepam	2836	IV	N	Nobrium
Mefenorex	1580	IV	N	Anorexic, Amexate, Doracil, Pondinil
Meperidine	9230	II	Y	Demerol, Mepergan, pethidine
Meperidine intermediate-A	9232	II	Y	Meperidine precursor
Meperidine intermediate-B	9233	II	Y	Meperidine precursor, normeperidine
Meperidine intermediate-C	9234	II	Y	Meperidine precursor
Mephedrone (4-Methyl-N-methylcathinone)	1248	I	N	(Positional Isomers: 3-Methyl-methcathinone, Buphedrone, Ethcathinone, N,N-Dimethyl-cathinone)
Meproamate	2820	IV	N	Miltown, Equanil, Micrainin, Equagesic, Meprospan
Mescaline	7381	I	N	Constituent of "Peyote" cacti
Mestanolone (17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one)	4000	III	N	Assimil, Ermalone, Methybol, Tantarone
Mesterolone (1alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one)	4000	III	N	Androviron, Proviron, Testiwop
Metazocine	9240	II	Y	
Methadone	9250	II	Y	Dolophine, Methadose, Amidone
Methadone intermediate	9254	II	Y	Methadone precursor
Methamphetamine	1105	II	N	Desoxyn, D-desoxyephedrine, ICE, Crank, Speed
Methandienone (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one)	4000	III	N	Dianabol, Metabolina, Nerobol, Perbolin
Methandriol (17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene)	4000	III	N	Sinesex, Stenediol, Troformone
Methaqualone	2565	I	N	Quaalude, Parest, Somnafac, Opitimil, Mandrax
Methasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one)	4000	III	N	Methasterone; 2 α ,17 α -dimethyl-17 β -hydroxy-5 α -androstan-3-one
Methcathinone	1237	I	N	N-Methylcathinone, "cat"
Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one)	4000	III	N	Primobolan, Primobolan Depot, Primobolan S
Methohexital	2264	IV	N	Brevital
Methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3- methylbutanoate	7021	I	N	FUB-AMB, MMB- FUBINACA, AMB-FUBINACA
Methyl-desorphine	9302	I	Y	
Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one)	4000	III	N	
Methyldihydromorphine	9304	I	Y	
Methylone (3,4-Methylenedioxy-N-methylcathinone)	7540	I	N	(Positional Isomer: 2,3-methylenedioxy-methylcathinone (2,3-MDMC, 1-(benzo[d][1,3]dioxol-4-yl)-2-(methylamino)propan-1-one))
Methylphenidate	1724	II	N	Concerta, Ritalin, Methylin

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Methylphenobarbital (mephobarbital)	2250	IV	N	Mebaral, mephobarbital
Methyltestosterone (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Android, Oreton, Testred, Virilon
Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9,11-trien-3-one)	4000	III	N	Metribolone
Methyprylon	2575	III	N	Noludar
Metopon	9260	II	Y	
Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one)	4000	III	N	Cheque, Matenon
Midazolam	2884	IV	N	Versed
MMB-CHMICA, AMB-CHMICA (methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate)	7044	I	N	
Modafinil	1680	IV	N	Provigil
Moramide-intermediate	9802	II	Y	
Morpheridine	9632	I	Y	
Morphine	9300	II	Y	MS Contin, Roxanol, Oramorph, RMS, MSIR
Morphine combination product/50 mg/(100 ml or 100 gm)	9810	III	Y	
Morphine methylbromide	9305	I	Y	
Morphine methylsulfonate	9306	I	Y	
Morphine-N-oxide	9307	I	Y	
MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine))	9560	I	Y	MT-45
Myrophine	9308	I	Y	
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide	9843	I	Y	Tetrahydrofuranlyl fentanyl
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide	9816	I	Y	Ortho-fluorofentanyl or 2-fluorofentanyl
N,N-Dimethylamphetamine	1480	I	N	
Nabilone	7379	II	N	Cesamet
Nalorphine	9400	III	Y	Nalline
Nandrolone (17beta-hydroxyestr-4-en-3-one)	4000	III	N	Deca-Durabolin, Durabolin, Durabolin-50
Naphyrone	1258	I	N	naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Positional Isomer: α-naphyrone)
N-Benzylpiperazine	7493	I	N	BZP, 1-benzylpiperazine
N-Ethyl-1-phenylcyclohexylamine	7455	I	N	PCE
N-Ethyl-3-piperidyl benzilate	7482	I	N	JB 323
N-Ethylamphetamine	1475	I	N	NEA
N-Ethylpentylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one)	7543	I	N	Ephylone
N-Hydroxy-3,4-methylenedioxyamphetamine	7402	I	N	N-hydroxy MDA

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Nicocodeine	9309	I	Y	
Nicomorphine	9312	I	Y	Vilan
Nimetazepam	2837	IV	N	Erimin
Nitrazepam	2834	IV	N	Mogadon
NM2201; CBL2201 (Naphthalen-1-yl 1-(5-fluoropentyl)-1 H-indole-3-carboxylate)	7221	I	N	
N-Methyl-3-piperidyl benzilate	7484	I	N	JB 336
Noracymethadol	9633	I	Y	
Norbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one)	4000	III	N	Genabol
Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one)	4000	III	N	Anabol-4-19, Lentabol
Nordiazepam	2838	IV	N	Nordazepam, Demadar, Madar
Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one)	4000	III	N	Nilevar, Pronabol, Solevar
Norlevorphanol	9634	I	Y	
Normethadone	9635	I	Y	Phenyldimazone
Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one)	4000	III	N	Lutenin, Matronal, Orgasteron
Normorphine	9313	I	Y	
Norpipanone	9636	I	Y	
Ocfentanil	9838	I	Y	N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide
Opium combination product 25 mg/du	9809	III	Y	Paregoric, other combination products
Opium extracts	9610	II	Y	
Opium fluid extract	9620	II	Y	
Opium poppy	9650	II	Y	Papaver somniferum
Opium preparations - 100 mg/(100 ml or 100 gm)		V	Y	Parepectolin, Kapectolin PG, Kaolin Pectin P.G.
Opium tincture	9630	II	Y	Laudanum
Opium, granulated	9640	II	Y	Granulated opium
Opium, powdered	9639	II	Y	Powdered opium
Opium, raw	9600	II	Y	Raw opium, gum opium
Oripavine	9330	II	Y	
Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-5alpha-androstan-3-one)	4000	III	N	Anavar, Lonavar, Oxandrin, Provitar, Vasorome
Oxazepam	2835	IV	N	Serax, Serenid-D
Oxazolam	2839	IV	N	Serenal, Converal
Oxycodone	9143	II	Y	OxyContin, Percocet, Endocet, Roxicodone, Roxicet,
Oxymesterone (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one)	4000	III	N	Anamidol, Balnimax, Oranabol, Oranabol 10

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Oxymetholone (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-5alpha-androstan-3-one)	4000	III	N	Anadrol-50, Adroyd, Anapolon, Anasteron, Pardroyd
Oxymorphone	9652	II	Y	Numorphan
Para-chloroisobutyryl fentanyl	9826	I	Y	N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide
Para-fluorobutyryl fentanyl	9823	I	Y	N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
Para-Fluorofentanyl	9812	I	Y	China White, fentanyl
Parahexyl	7374	I	N	Synhexyl,
Paraldehyde	2585	IV	N	Paral
Para-methoxybutyryl fentanyl	9837	I	Y	N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate)	7222	I	N	QUPIC; PB-22
Pemoline	1530	IV	N	Cylert
Pentazocine	9709	IV	N	Talwin, Talwin NX, Talacen, Talwin Compound
Pentedrone (α-methylaminovalerophenone)	1246	I	N	2-(methylamino)-1-phenylpentan-1-one)(Positional Isomers:3-methylethcathinone (3-MEC), 4-ethylmethcathinone (4-EMC), 4-methylbuphedrone (4-MeMABP;4-MeBP), 3,4-dimethylmethcathinone (3,4-DMMC),N-ethylbuphedrone (NEB),N-ethyl-N-methylcathinone(EMC))
Pentobarbital	2270	II	N	Nembutal
Pentobarbital & noncontrolled active ingred.	2271	III	N	FP-3
Pentobarbital suppository dosage form	2271	III	N	WANS
Pentylone	7542	I	N	bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one) (Positional Isomers: dibutylone (bk-DMBDB) and propylone (3',4'-methylenedioxy-N-propylaminocathinone, 1-(benzo[d][1,3]dioxol-5-yl)-2-(propylamino)propan-1-one))
Perampanel	2261	III	N	Fycompa, [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile]
Petrichloral	2591	IV	N	Pentaerythritol chloral, Periclor
Peyote	7415	I	N	Cactus which contains mescaline
Phenadoxone	9637	I	Y	
Phenampromide	9638	I	Y	
Phenazocine	9715	II	Y	Narphen, Prinadol
Phencyclidine	7471	II	N	PCP, Sernylan
Phendimetrazine	1615	III	N	Plegine, Prelu-2, Bontril, Melfiat, Statobex
Phenmetrazine	1631	II	N	Preludin
Phenobarbital	2285	IV	N	Luminal, Bellergal-S
Phenomorphan	9647	I	Y	
Phenoperidine	9641	I	Y	Operidine, Lealgin

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Phentermine	1640	IV	N	Ionamin, Fastin, Adipex-P, Obe-Nix, Zantryl
Phenylacetone	8501	II	N	P2P, phenyl-2-propanone, benzyl methyl ketone
Pholcodine	9314	I	Y	Copholco, Adaphol, Codisol, Lantuss, Pholcolin
Piminodine	9730	II	Y	
Pinazepam	2883	IV	N	Domar
Pipradrol	1750	IV	N	Detaril, Stimolag Fortis
Piritramide	9642	I	Y	Piridolan
Poppy Straw	9650	II	Y	Opium poppy capsules, poppy heads
Poppy Straw Concentrate	9670	II	Y	Concentrate of Poppy Straw, CPS
Prazepam	2764	IV	N	Centrax
Pregabalin	2782	V	N	Lyrica
Proheptazine	9643	I	Y	
Properidine	9644	I	Y	
Propiram	9649	I	Y	Algeril
Prostanazol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole)	4000	III	N	Prostanazol; [3,2-c]pyrazole-5 α -androstano-17 β -ol
Psilocybin	7437	I	N	Constituent of "Magic mushrooms"
Psilocyn	7438	I	N	Psilocin, constituent of "Magic mushrooms"
Pyrovalerone	1485	V	N	Centroton, Thymergix
Quazepam	2881	IV	N	Doral
Racemethorphan	9732	II	Y	
Racemoramide	9645	I	Y	
Racemorphan	9733	II	Y	Dromoran
Remifentanil	9739	II	Y	Ultiva
Secobarbital	2315	II	N	Seconal, Tuinal
Secobarbital & noncontrolled active ingred	2316	III	N	
Secobarbital suppository dosage form	2316	III	N	
Sibutramine	1675	IV	N	Meridia
SPA	1635	IV	N	1-dimethylamino-1,2-diphenylethane, Lefetamine
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole)	7008	I	N	SR-18 and RCS-8
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole)	7104	I	N	SR-19 and RCS-4
Stanozolol (17alpha-methyl-17beta-hydroxy-5alpha-androst-2-eno[3,2-c]-pyrazole)	4000	III	N	Winstrol, Winstrol-V
Stenbolone (17beta-hydroxy-2-methyl--5alpha-androst-1-en-3-one)	4000	III	N	
Stimulant compounds previously excepted	1405	III	N	Mediatric
Sufentanil	9740	II	Y	Sufenta

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Sulfondiethylmethane	2600	III	N	
Sulfonethylmethane	2605	III	N	
Sulfonmethane	2610	III	N	
Suvorexant	2223	IV	N	MK-4305, [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
Talbutal	2100	III	N	Lotusate
Tapentadol	9780	II	Y	
Temazepam	2925	IV	N	Restoril
Testolactone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone)	4000	III	N	Teolit, Teslac
Testosterone (17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Android-T, Androlan, Depotest, Delatestryl
Tetrahydrocannabinols	7370	I	N	THC, Delta-8 THC, Delta-9 THC, dronabinol and others
Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one)	4000	III	N	THG
Tetrazepam	2886	IV	N	Myolastan, Musaril
Thebacon	9315	I	Y	Acetylhydrocodone, Acedicon, Thebacetyl
Thebaine	9333	II	Y	Precursor of many narcotics
Thiafentanil	9729	II	Y	Thianil
Thiamylal	2100	III	N	Surital
Thiofentanyl	9835	I	Y	Chine white, fentanyl
Thiopental	2100	III	N	Pentothal
THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone	7024	I	N	THJ-2201
Tiletamine & Zolazepam Combination Product	7295	III	N	Telazol
Tilidine	9750	I	Y	Tilidate, Valoron, Kitadol, Lak, Tilsa
Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol)	9752	IV	Y	Tramadol
Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one)	4000	III	N	Finaplix-S, Finajet, Parabolan
Triazolam	2887	IV	N	Halcion
Trimeperidine	9646	I	Y	Promedolum
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)	9547	I	Y	U-47700
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	7144	I	N	UR-144
Valeryl fentanyl	9840	I	Y	N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide
Vinbarbital	2100	III	N	Delvinal, vinbarbitone
Zaleplon	2781	IV	N	Sonata
Zolpidem	2783	IV	N	Ambien, Ivadal, Stilnoct, Stilnox
Zopiclone	2784	IV	N	Lunesta

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
-----------	---------------	------------	------	-------------

Abbreviations: "NARC"= Narcotic, "CSA SCH"= CSA Schedule

Controlled Substances - Alphabetical Order
10-Dec-18

Schedule of Administrative Fees

In accordance with OAR 107-001-030 and 855-110-0015(4), the Board of Pharmacy established the following fees: Upon request fees may be waived as specified in OAR 855-110-0015(7).

1. General:

Provide an estimate of costs for the services requested:	No charge
The first 30 minutes of staff time to provide the information requested:	No charge
After 30 minutes, staff time will be charged at:	
(i) Administrative staff time:	\$25 per hour in increments of 15 minutes;
(ii) Management or pharmacist time:	\$40 per hour in increments of 15 minutes;
(iii) IT Consultant time	\$75 per hour or part thereof;
(iv) Department of Justice (DOJ) attorney fees:	Actual costs as billed to the agency by DOJ.

2. Duplication and delivery of records:

Each page printed or copied after the first 10:	\$0.07 B/W, \$0.40 color per page.
Records provided on digital media such as CD, or any other media:	\$5 / CD Other media at actual cost.
Electronic mail message including attachments:	No charge, however staff time may apply.
Mail or other delivery service:	Actual cost.
Electronic lists of licensees and registrants:	\$80 per category
Electronic lists of <u>individual</u> licensees BASIC list (name, mailing address, public email address)	\$25 per category, this does not apply to outlets
Manual license verification:	\$10 per license number (including lapsed and inactive numbers).
Certified copies (two per page)	No charge for first page \$5 per additional page
Duplicate wall certificates:	\$20 each

4. Publications:

Copies of Laws and Rules (available free through the Board web site):	\$25 per CD or paper set for delivery within the USA; \$25 plus actual delivery costs for delivery outside the USA;
---	--

2019 APRIL / C4

OREGON

ATTORNEY GENERAL'S

ADMINISTRATIVE LAW MANUAL

AND

UNIFORM AND MODEL RULES OF

PROCEDURE

UNDER THE

ADMINISTRATIVE PROCEDURES ACT



ELLEN F. ROSENBLUM
Attorney General

July 2014

**OREGON BOARD OF PHARMACY
PER DIEM & EXPENSE REIMBURSEMENT POLICY**

PER DIEM AND EXPENSES

The following Oregon Statutes (ORS) guide the Board's policy for Per Diem compensation and reimbursement for expenses - ORS 292.210 - 292.250, 292.495, 689.115(4), 689.175(1), ORS, 689.645, 2017 OL Ch. 106:

292.495 Compensation and expenses of members of state boards and commissions. (1) Subject to the availability of funds therefor in the budget of the state board or commission, and except as otherwise provided by law, *any member of a state board or commission, other than a member who is employed in full-time public service*, who is authorized by law to receive compensation for time spent in performance of official duties, *shall receive a payment of \$30 for each day or portion thereof during which the member is actually engaged in the performance of official duties.*

(2) Except as otherwise provided by law, *all members of state boards and commissions, including those employed in full-time public service, may receive actual and necessary travel or other expenses actually incurred in the performance of their official duties within the limits provided by law or by the Oregon Department of Administrative Services under ORS 292.210 to 292.250.*

(3) As used in subsection (2) of this section, "other expenses" includes expenses incurred by a member of a state board or commission in employing a substitute to perform duties, including personal, normally performed by the member which the member is unable to perform because of the performance of official duties and which by the nature of such duties cannot be delayed without risk to health or safety. No member shall be reimbursed for expenses incurred in employing a substitute in excess of \$25 per day. [1969 c.314 §1; 1973 c.224 §2; 1975 c.441 §1; 1979 c.616 §1]

689.115(4) OBOP Compensation

(4) Members of the board are entitled to compensation and expenses as provided in ORS 292.495. *The board may provide by rule for compensation to board members for the performance of official duties at a rate that is greater than the rate provided in ORS 292.495.* [1979 c.777 §§7,8,9,11; 1987 c.108 §2; 2009 c.535 §29]

689.175 Compensation of board members (1) Each member of the State Board of Pharmacy shall receive compensation for each day on which the member is engaged in performance of the official duties of the board, and reimbursement for all expenses incurred in connection with the discharge of such official duties as provided in ORS 292.495.

2017 OL Ch. 106 – Public Health and Pharmacy Formulary Advisory Committee

(5) Members of the committee are entitled to compensation and expenses as provided in ORS 292.495, to be paid by the State Board of Pharmacy.

COMPENSATION

Board members and Public Health and Pharmacy Formulary Advisory Committee appointees authorized by ORS 292.495(1) may choose if eligible, to receive up to \$100 daily allowable per diem adopted under OAR 855-010-0020 when attending a Board of Pharmacy Board or Public Health and Pharmacy Formulary Advisory Committee meeting that lasts a minimum of three hours. Travel time and preparation time for meetings will not be compensated other than when there is an allowable expense reimbursement.

For the purpose of compensation, a board member or Public Health and Pharmacy Formulary Advisory Committee appointee is considered engaged in the performance of official duties when:

- ❖ The activity furthers the Board's mission; and
- ❖ Attending a board meeting; or
- ❖ Attending a Public Health & Pharmacy Formulary Advisory Committee meeting; or
- ❖ Engaged in an activity which is either at the request of the board chair or authorized by a vote of the board in advance of the activity.
- ❖ All per diem shall be calculated as whichever amount is the greater of :
 - a) \$50 after a minimum of three hours of service daily; or
 - b) \$100 after a minimum of six hours of service.

Note -1 : 292.495(1) does not allow a member who is employed in full-time public service to receive compensation.

*Note -2 : The Board **has** elected to adopt a rule as 689.115(4) allows to be compensated at a rate that is greater than the \$30 listed in ORS 292.495.*

Board/Committee members will report meetings and activities to staff and they will process per diem assignments monthly. In the interest of efficiency and cost savings, all members have been asked to set up *direct deposit* for per diem.

EXPENSE REIMBURSEMENT

Expenses incurred in the course of a Board/Committee Member's official duties will be reimbursed pursuant to ORS 292.210-292.250 and the Department of Administrative Services Fiscal Policies and Procedures identified in the Oregon Accounting Manual (OAM).

Reimbursements typically include mileage and hotel/meal reimbursement for individuals that have to travel to the Board office for Board/Committee meetings and require an overnight stay or anytime a member is required to travel to an out of state meeting to represent the Board.

Reimbursements are calculated based on the OAM allowable or actual and necessary if receipts are submitted.

Board/Committee Members are asked to submit reimbursement requests in a timely manner. Staff prepares the paperwork for signature and sends it to member's following each meeting or official activity. All members have been asked to set up direct deposit for reimbursements to reduce the overall cost to the agency.

BOARD OF PHARMACY
 AY19 CASH FLOW - JANUARY 2019
 OF Appn 30235

Object	LAB ORBITS BUDGET	Rstars Financial Plan	EBoard or Adj Budget or Salary Pot	Adjusted Financial Plan	ACTUALS To Date	Unobligated Balance	% Expended
REVENUE							
0205 Other Business Licenses	4,431,667	4,431,667		4,431,667	3,586,899	844,769	81%
0210 Other NonBusiness Licenses and Fe	505,552	505,552		505,552	180,243	325,309	36%
0505 Fines and Forfeits	420,000	420,000		420,000	278,892	141,108	66%
0605 Interest and Investments	48,000	48,000		48,000	138,483	(90,483)	289%
0975 Other Revenue	39,700	39,700		39,700	79,181	(39,481)	199%
SubTotal Revenue	5,444,919	5,444,919	0	5,444,919	4,263,697	1,181,222	78%
TRANSFERS							
2443 Transfer out to OHA--Workforce/PD	(409,357)	(409,357)		(409,357)	32,961	(442,318)	-8%
SubTotal Transfers	(409,357)	(409,357)	0	(409,357)	32,961	(442,318)	-8%
TOTAL REVENUE & TRANSFERS	5,035,562	5,035,562	0	5,035,562	4,230,736	1,623,540	84%
PERSONAL SERVICES							
3110 Regular Employees	3,191,268	3,191,268	104,724	3,295,992	2,508,310	787,681.92	76%
Board Member Stipends	-	-		0	-	-	
3160 Temporary Appointments	25,222	25,222		25,222	-	25,222	0%
3170 Overtime Payments	-	-		0	505	(505)	0%
3190 All Other Differential O/Class Lead V	183,457	183,457		183,457	147,615	35,842	80%
3210 Employment Relations Board Asses	1,083	1,083		1,083	807	276	74%
3220 Public Employees Retirement Contri	504,012	504,012	3,269	507,281	364,554	142,727	72%
3221 Pension Bond Contribution	195,224	195,224	(3,502)	191,722	156,056	35,666	81%
3230 Social Security Taxes	256,020	256,020		256,020	190,767	65,253	75%
3240 Unemployment Assessment	-	-		0	1,869	(1,869)	0%
3250 Workers' Compensation Assesmen	1,380	1,380		1,380	773	607	56%
3260 Mass Transit Tax	20,334	20,334		20,334	15,837	4,497	78%
3270 Flexible Benefits	666,720	666,720	24,720	691,440	494,937	196,503	72%
3455 Vacancy Savings-ORBITS only	(169,448)	(169,448)	-	(169,448)	-	(169,448)	0%
3465 Reconciliation Adjustment-ORBITS only	-	-		0	-	-	0%
3470 Undistributed Personal Services-ORBITS	-	-		0	-	-	0%
3991 PERS Policy Adjustment-ORBITS	-	-		0	-	-	0%
SubTotal Personal Services	4,875,272	4,875,272	129,211	5,004,483	3,882,031	1,122,452	78%
SERVICES AND SUPPLIES							
4100 InState Travel	102,270	102,270		102,270	71,829	30,441	70%
4125 Out of State Travel	15,724	15,724		15,724	6,325	9,399	40%
4150 Employee Training	52,335	52,335		52,335	17,269	35,066	33%
4175 Office Expenses	123,883	123,883		123,883	66,931	56,952	54%
4200 Telecommunications	43,879	43,879		43,879	45,973	(2,094)	105%
4225 State Govt. Service Chgs.	119,969	119,969		119,969	130,609	(10,640)	109%
4250 Data Processing	73,694	73,694		73,694	54,146	19,548	73%
4275 Publicity & Publications	37,712	37,712		37,712	7,293	30,419	19%
4300 Professional Services	402,408	402,408		402,408	214,691	187,717	53%
4315 IT Professional Services	353,340	353,340		353,340	32,550	320,790	9%
4325 Attorney General	326,595	326,595	86,083	412,678	361,310	51,369	88%
4375 Employee Recruitment & Develop	207	207		207	-	207	0%
4400 Dues & Subscriptions	4,583	4,583		4,583	4,532	51	99%
4425 Facilities Rent & Taxes	219,519	219,519		219,519	142,480	77,039	65%
4475 Facilities Maintenance	51	51		51	116	(65)	228%
4525 Medical Supplies and Services	1,110	1,110		1,110	4,178	(3,068)	376%
4575 Agency Program Related S&S	229,434	229,434		229,434	149,073	80,361	65%
4650 Other Services & Supplies	278,652	278,652		278,652	242,974	35,678	87%
4700 Expendable Property	10,499	10,499		10,499	689	9,810	7%
4715 IT Expendable Property	43,976	43,976		43,976	4,553	39,423	10%
5550 Data Processing Software	-	-		0	-	-	0%
5600 Data Processing Hardware	8,296	8,296		8,296	0	8,296	0%
SubTotal Services and Supplies	2,448,136	2,448,136	86,083	2,534,219	1,557,522	976,698	61%
SPECIAL PAYMENTS							
6085 Other Special Payments	11,991	11,991		11,991	-	11,991	0%
6443 Special Payments to OHA-HPSP	-	-		-	-	-	0%
SubTotal Transfers	11,991	11,991	0	11,991	0	11,991	0%
Total Expenditures Budget	7,335,399	7,335,399	215,294	7,550,693	5,439,552	2,111,141	72%
				7,057,070			
LAB % PS	66%			66%		Target	100%
LAB % S&S	33%			34%			
LAB % SP	0%			0%			

AY17 Ending Cash Balance	Cash	4,794,930
Revenue less Expenditures	Actuals	
Total Revenue & Transfers	4,230,736	
Total Expenditures	(9,439,552)	
Total Revenues & Transfers less Expenditures	(1,208,816)	(1,208,816)
AY19 Cash Balance after the Fiscal Month Closed		3,586,114
Budgeted Revenues not yet received (zero) less Estimated Transfers to OHA-PMP & Workforce Data program to be mac		0
Budgeted Expenditures not yet spent		(2,111,141)
AY19 Estimated Cash Balance		1,474,973
Cash Balance Contingency (Months)		4.69 months

Revenue received is more than budgeted so zero is not yet received